Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

导出原文传递

翻译打印收藏纠错

作者： Schnell,D. ^[1] ; Buschke,S. ^[2] ; Fuchs,H. ^[3] ; Gansser,D. ^[4] ; Goeldner,R.-G. ^[5] ; Uttenreuther-Fischer,M. ; Stopfer,P. ; Wind,S. ; Petersen-Sylla,M. ; Halabi,A. ; Koenen,R.

作者单位： Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH and Co. KG ^[1] Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach ^[2] Clinical Research Services (CRS), Kiel GmbH, Kiel, Germany ^[3] Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany ^[4] Clinical Development and Medical Affairs, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach ^[5]

关键词 Afatinib Epidermal growth factor receptor (EGFR)Hepatic impairment Human Pharmacokinetics Tyrosine kinase inhibitor

发布时间 2014-12-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交